BCI
KLRA

Bain Capital Investors’s Kailera Therapeutics KLRA Stock Holding History

Bain Capital Investors’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$578M Buy
+26,255,581
New +$577M 12.01% 5

Other funds holding KLRA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bain Capital Investors's KLRA Position: Q2 2026 in Review

Bain Capital Investors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 26,255,581 shares worth $578M. The stake represents 12.01% of the portfolio and ranks #5 among its holdings.

85 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Bain Capital Investors held 26,255,581 shares of Kailera Therapeutics worth $578M as of Q2 2026.
  • Kailera Therapeutics was a new Bain Capital Investors position in Q2 2026.
  • Kailera Therapeutics made up 12.01% of Bain Capital Investors's portfolio in Q2 2026, its #5 holding.
  • 85 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Bain Capital Investors's 13F filing for Q2 2026, filed 14 Aug 2026.